Novo Nordisk to cap insulin prices in Minnesota settlement
Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Novo Nordisk’s Ozempic Gets FDA Approval
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
including CEO of obesity drugmaker Novo Nordisk, met with the government. Denmark's Prime Minister Mette Frederiksen ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback